Fortunately, these new HER2-directed agents have shown great efficacy in treating brain metastases and thus can delay the need for whole brain irradiation and its accompanying toxicity (most notably cognitive impairment) [2, 22–24]. This evidence concerns the gene ERBB2 and Cognitive impairment.